Sabby Management’s Can-Fite BioPharma American Depositary Shares CANF Stock Holding History

Sabby Management’s Portfolio CANF Stock Details CANF Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-42,559	Closed	-$132K	–	27
2026 Q1	$132K	Buy	+42,559	New	+$176K	0.29%	20
2025 Q4	–	Sell	-70,303	Closed	-$871K	–	39
2025 Q3	$871K	Buy	70,303 +31,316	+80%	+$478K	1.01%	10
2025 Q2	$819K	Buy	+38,987	New	+$898K	1.48%	10
2019 Q3	–	Sell	-1,059	Closed	-$610K	–	97
2019 Q2	$610K	Buy	+1,059	New	+$1.16M	0.77%	28
2018 Q3	–	Sell	-37	Closed	-$130K	–	131
2018 Q2	$130K	Sell	37 -372	-91%	-$1.48M	0.02%	110
2018 Q1	$1.77M	Buy	+409	New	+$2.26M	0.21%	43
2017 Q2	–	Sell	-10	Closed	-$57K	–	225
2017 Q1	$57K	Buy	+10	New	+$60.7K	﹤0.01%	245

Other funds holding CANF

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

RhumbLine Advisers Boston, Massachusetts $133B AUM 43.5% 1-Year Est. Return

Fifth Third Bancorp Cincinnati, Ohio $61.7B AUM 33.76% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

AWM

Activest Wealth Management Aventure, Florida $518M AUM 44.34% 1-Year Est. Return

TWC

TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Sabby Management's CANF Position: Q2 2026 in Review

Sabby Management sold out of Can-Fite BioPharma American Depositary Shares (CANF) in Q2 2026, closing a stake of 42,559 shares — an estimated $132K sold.

Sabby Management first reported a position in CANF in Q1 2017 and held it in 7 quarters. The position peaked at $1.77M in Q1 2018. 8 funds tracked by Wall St. Rank hold CANF as of Q2 2026.

Sabby Management reported no remaining Can-Fite BioPharma American Depositary Shares position as of Q2 2026 after selling out during the quarter.
Sabby Management sold 42,559 Can-Fite BioPharma American Depositary Shares shares in Q2 2026, an estimated $132K.
Sabby Management first reported a position in Can-Fite BioPharma American Depositary Shares in Q1 2017 and held it in 7 quarters.
Sabby Management's Can-Fite BioPharma American Depositary Shares position peaked at $1.77M in Q1 2018.
8 funds tracked by Wall St. Rank held Can-Fite BioPharma American Depositary Shares as of Q2 2026.

Based on Sabby Management's 13F filing for Q2 2026, filed 14 Aug 2026.